|
WO2020247574A1
|
|
Methods of purifying masked antibodies
|
|
WO2020247572A1
|
|
Masked antibody formulations
|
|
US2020246479A1
|
|
Anti-cd228 antibodies and antibody-drug conjugates
|
|
TW202042820A
|
|
Methods of treating breast cancer with tucatinib
|
|
WO2020132655A1
|
|
Adcs with thiol multiplex linkers
|
|
WO2020132096A1
|
|
Controlled fucosylation of antibodies
|
|
WO2020072519A1
|
|
Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
|
|
TW202024043A
|
|
Alternative processes for the preparation of tubulysins and intermediates thereof
|
|
TW202015740A
|
|
Camptothecin conjugates
|
|
AR114473A1
|
|
PEPTIDE-CAMPTOTECHIN CONJUGATES
|
|
CN112189020A
|
|
Use of antibody drug conjugates comprising tubulin disruptors for the treatment of solid tumors
|
|
CN111989339A
|
|
Hydrophobic auristatin F compounds and conjugates thereof
|
|
WO2019161174A1
|
|
Glypican 3 antibodies and conjugates thereof
|
|
BR112020010937A2
|
|
humanized anti-liv1 antibodies for the treatment of breast cancer
|
|
CN111448213A
|
|
CD47 antibodies and their use for treating cancer
|
|
CN111344001A
|
|
Acid-mediated assays for ligand-drug conjugates
|
|
AR115184A1
|
|
SIDE EFFECT REDUCTION METHODS OF ANTI-CD30-DRUG ANTIBODY CONJUGATE TREATMENT
|
|
WO2019075188A1
|
|
Modulating the immune response using antibody-drug conjugates
|
|
CA3078737A1
|
|
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
TW201920128A
|
|
Process for the preparation of TUBULYSINS and intermediates thereof
|
